

REMARKS

Claims 21-24 are currently active.

Applicant wishes to thank the Examiner for the detailed analysis identified in the Office Action.

The specification has been amended. Table 1 has been deleted on page 19 and instead is inserted on page 37.

The Examiner has objected to the specification as failing to provide proper antecedent basis for the claimed subject matter. The language of Claims 21-24 has been introduced into the specification to obviate this objection.


The Examiner has rejected Claims 21-24 under 35 U.S.C. 101. Any reference to alphafetoprotein protein receptor binding sites in the claims has been deleted. There is now identified only one antigen.

The Examiner has rejected Claims 21-24 under 35 U.S.C. 112. Claim 21 has been amended to delete the language "an increased level". It is believed that this amendment obviates this rejection.

In view of the foregoing amendments and remarks, it is respectfully requested that the outstanding rejections and objections to this application be reconsidered and withdrawn, and Claims 21-24, now in this application be allowed.

Respectfully submitted,

RICARDO J. MORO

By 

Ansel M. Schwartz, Esquire

Reg. No. 30,587

One Sterling Plaza

201 N. Craig Street


Suite 304

Pittsburgh, PA 15213

(412) 621-9222

Attorney for Applicant

CERTIFICATE OF MAILING
I hereby certify that this correspondence
is being deposited with the U.S. Postal
Service as first class mail in an envelope
addressed to: Commissioner for Patents,
P.O. Box 1450, Arlington, VA 22313-
1450 on 4/19/06


Ansel M. Schwartz
Registration No. 30,587